TGFB1 and idiopathic pulmonary fibrosis: Although there is no treatment for fibrosis in the myocardium, recently two drugs, pirfenidone and nintedanib have been approved for the treatment of idiopathic pulmonary fibrosis and exert their effects by inhibiting TGF-β, platelet-derived growth factor (PDGF) and FGF receptors, respectively, which are known regulators of LOXL2 expression [110].